search
Back to results

Exercise in Breast Cancer Survivors

Primary Purpose

Breast Cancer

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Aerobic Exercise
Sponsored by
Norwegian School of Sport Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Breast Cancer

Eligibility Criteria

28 Years - 72 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Eligible BCS must be listed in the Norwegian Cancer registry
  • Female
  • Adult-onset breast cancer diagnosis, diagnosed between 2008 and 2012
  • 60 years or younger at the time of diagnosis
  • received anthracycline-based chemotherapy as a part of their treatment history
  • signed informed consent and medical doctors approveal of participation prior to inclusion

Exclusion Criteria:

  • Received Herceptin
  • Diagnosed with stage IV breast cancer
  • Relapse since diagnosis
  • A history, or current presence, of another diagnosis of invasive cancer of any kind
  • Selfreported severe fatigue
  • present with any uncontrolled- or recent cardiovascular disease, has undergone heart surgery or uses a pacemaker
  • currently exercising more than 90 minutes per week

Sites / Locations

  • Norwegian School of Sport Sciences

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

No Intervention

Other

Arm Label

Aerobic Exercise

Standard care

Reference Group

Arm Description

The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.

Participants in this arm will not receive any follow-up on exercise during the intervention period.

Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm

Outcomes

Primary Outcome Measures

Change in VO2peak
Peak oxygen uptake during a treadmill based cardiopulmonary exercise test

Secondary Outcome Measures

Systolic- and diastolic heart chamber dimensions
Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography
Systolic- and diastolic longitudinal strain
Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography
Lean body mass
Body composition will be assessed by dual x-ray absorptiometry
Fat mass
Body composition will be assessed by dual x-ray absorptiometry
Blood volume
Hemoglobin mass and blood volume will be assessed using the carbon monoxide rebreathing method
Muscle fiber type
Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Muscle fiber area
Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Muscle mitochondria mass
Change in mitochondrial proteins will be assessed in muscle biopsies using western blot
Quality of life: Quality of Life Questionnaire (QLQ) C-30
Relevant patient reported outcomes will be obtained using validated Quality of Life Questionnaire (QLQ) C-30
Genome-wide DNA methylation and gene expression
For a sub-group of participants, muscle biopsies will be further processed for RNA and DNA

Full Information

First Posted
March 6, 2020
Last Updated
March 2, 2023
Sponsor
Norwegian School of Sport Sciences
Collaborators
Oslo University Hospital, Memorial Sloan Kettering Cancer Center, University of Oslo
search

1. Study Identification

Unique Protocol Identification Number
NCT04307407
Brief Title
Exercise in Breast Cancer Survivors
Official Title
The Cause Trial: A Randomized Trial of Aerobic Exercise on CVD Risk Factors in Breast Cancer Survivors
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
September 8, 2020 (Actual)
Primary Completion Date
March 2, 2023 (Actual)
Study Completion Date
March 2, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Norwegian School of Sport Sciences
Collaborators
Oslo University Hospital, Memorial Sloan Kettering Cancer Center, University of Oslo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the effects of aerobic exercise to usual care in women treated with chemotherapy and radiation therapy for non-metastatic breast cancer
Detailed Description
In this study, we will compare the effects of exercise between women previously treated with breast cancer to women with no history of any cancers. Therefore, in addition to a randomized controlled trial in women with previous breast cancer (i.e., an exerciser group and a control group), we also include a reference group comprising age-matched women with no history of any cancer diagnosis. Women in the reference group will undergo a similar exercise intervention and the exercise group. This study recruits through invitation only. The primary endpoint in this study is the change in cardiorespiratory fitness, measured as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, endpoints derived from the cardiopulmonary exercise test and lung function assessments, cellular muscle endpoints derived from muscle biopsies obtained from m. vastus lateralis, also patient-reported outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
210 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aerobic Exercise
Arm Type
Experimental
Arm Description
The aim is for participants to complete three weekly sessions of supervised aerobic treadmill based exercise for five months. Session duration varies from 20-60 minutes, with exercise intensity ranging from 55-95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate), will be determined by the CPET performed by certified exercise physiologists at baseline.
Arm Title
Standard care
Arm Type
No Intervention
Arm Description
Participants in this arm will not receive any follow-up on exercise during the intervention period.
Arm Title
Reference Group
Arm Type
Other
Arm Description
Participants in this arm are age-matched women with no history of any malignant disease, which will undergo similar assessments at baseline and post-intervention and also follow similar exercise intervention as the breast cancer survivors randomized to the Aerobic exercise arm
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Exercise
Intervention Description
Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
Primary Outcome Measure Information:
Title
Change in VO2peak
Description
Peak oxygen uptake during a treadmill based cardiopulmonary exercise test
Time Frame
From baseline to five months (post-intervention)
Secondary Outcome Measure Information:
Title
Systolic- and diastolic heart chamber dimensions
Description
Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography
Time Frame
From baseline to five months (post-intervention)
Title
Systolic- and diastolic longitudinal strain
Description
Cardiac morphology and function will be assessed by 2D and 3D Echocardiography and 2D strain echocardiography
Time Frame
From baseline to five months (post-intervention)
Title
Lean body mass
Description
Body composition will be assessed by dual x-ray absorptiometry
Time Frame
From baseline to five months (post-intervention)
Title
Fat mass
Description
Body composition will be assessed by dual x-ray absorptiometry
Time Frame
From baseline to five months (post-intervention)
Title
Blood volume
Description
Hemoglobin mass and blood volume will be assessed using the carbon monoxide rebreathing method
Time Frame
From baseline to five months (post-intervention)
Title
Muscle fiber type
Description
Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time Frame
From baseline to five months (post-intervention)
Title
Muscle fiber area
Description
Change in muscle morphology will be assessed in muscle biopsies using immunohistochemistry
Time Frame
From baseline to five months (post-intervention)
Title
Muscle mitochondria mass
Description
Change in mitochondrial proteins will be assessed in muscle biopsies using western blot
Time Frame
From baseline to five months (post-intervention)
Title
Quality of life: Quality of Life Questionnaire (QLQ) C-30
Description
Relevant patient reported outcomes will be obtained using validated Quality of Life Questionnaire (QLQ) C-30
Time Frame
From baseline to five months (post-intervention)
Title
Genome-wide DNA methylation and gene expression
Description
For a sub-group of participants, muscle biopsies will be further processed for RNA and DNA
Time Frame
From baseline to five months (post-intervention)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
28 Years
Maximum Age & Unit of Time
72 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eligible BCS must be listed in the Norwegian Cancer registry Female Adult-onset breast cancer diagnosis, diagnosed between 2008 and 2012 60 years or younger at the time of diagnosis received anthracycline-based chemotherapy as a part of their treatment history signed informed consent and medical doctors approveal of participation prior to inclusion Exclusion Criteria: Received Herceptin Diagnosed with stage IV breast cancer Relapse since diagnosis A history, or current presence, of another diagnosis of invasive cancer of any kind Selfreported severe fatigue present with any uncontrolled- or recent cardiovascular disease, has undergone heart surgery or uses a pacemaker currently exercising more than 90 minutes per week
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tormod S Nilsen, PhD
Organizational Affiliation
The Norwegian School of Sport Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Norwegian School of Sport Sciences
City
Oslo
ZIP/Postal Code
0806
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Exercise in Breast Cancer Survivors

We'll reach out to this number within 24 hrs